Roth Capital Resumes Arcturus Therapeutics (ARCT) at Buy
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Price: $8.23 --0%
Rating Summary:
13 Buy, 5 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 17
Rating Summary:
13 Buy, 5 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 17
Join SI Premium – FREE
Roth Capital analyst Elemer Piros resumes coverage on Arcturus Therapeutics (NASDAQ: ARCT) with a Buy rating and a price target of $77.00.
For an analyst ratings summary and ratings history on Arcturus Therapeutics click here. For more ratings news on Arcturus Therapeutics click here.
Shares of Arcturus Therapeutics closed at $53.17 yesterday.
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Morgan Stanley Starts Target Hospitality (TH) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
